News
Significant gaps in arthritis subtype awareness among US adults underscore the need for improved health literacy and more ...
Some treatments for rheumatoid arthritis could increase cancer risk. One reason is because some cells in our immune system ...
Michaela Hagenhofer, General Manager, Commercial Operations at Johnson & Johnson Innovative Medicine, explains how J&J is ...
Zentiva Group has entered into a licence and supply agreement with pharmaceutical company Lupin for the commercialisation of ...
Lupin and Zentiva partner to commercialize Certolizumab Pegol biosimilar globally, sharing profits and investing in ...
This review discusses the features of oligoarticular, polyarticular, systemic, and psoriatic JIA and enthesitis-related ...
Long-term treatment with ixekizumab does not increase the incidence of malignant neoplasms in patients with psoriasis, PsA, ...
1d
Everyday Health on MSN6 Reasons People Quit Their Psoriatic Arthritis Medication — and Why You Shouldn’tWhen psoriatic arthritis symptoms are under control, you may be tempted to stop taking medication. Here’s why that’s a bad idea.
Patients with psoriatic arthritis who meet clinical criteria for minimal disease activity also tend to report good disease ...
It is indicated for various diseases including heumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic ...
Racial and ethnic diversity is lacking in PsA clinical trials, with non-White participants remaining severely underrepresented.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results